Pharma BD Deal Intelligence
Vertex agrees to acquire Exonics Therapeutics for $245M upfront plus up to $1B in milestones for gene editing therapies in muscular dystrophy
Vertex grows gene editing presence acquiring Exonics and expanding CRISPR Therapeutics collaboration for Duchenne muscular dystrophy
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Vertex acquired Exonics for up to $1B for Duchenne muscular dystrophy treatments.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated / Exonics Therapeutics (this deal) | 2005 | $1.0B | 54 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Vertex Pharmaceuticals Incorporated / Semma Therapeutics Inc. | 2019 | $950M | 86 |
| Vertex Pharmaceuticals Incorporated / Concert Pharmaceuticals, Inc. | 2017 | $250M | 85 |
| Vertex Pharmaceuticals Incorporated / CRISPR Therapeutics AG | 2015 | $2.6B | 85 |
| Vertex Pharmaceuticals Incorporated / Alpine Immune Sciences | 2024 | $4.9B | 78 |
| Vertex Pharmaceuticals Incorporated / Crinetics Pharmaceuticals, Inc. | 2026 | $10.0B | 68 |
← Browse all deals · How we score deals
More: 2005 deals · Vertex Pharmaceuticals Incorporated deals · Rare Disease deals